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A large retroperitoneal lymphatic
malformation successfully treated with
traditional Japanese Kampo medicine in
combination with surgery
Toko Shinkai* , Kouji Masumoto, Fumiko Chiba and Nao Tanaka
Abstract
Background: Current treatment options for lymphatic malformations (LMs) are multimodal. Recently, the effectiveness
of treating LMs with Eppikajyutsuto (TJ-28) has been reported. TJ-28 is a kind of oral herbal medicine classified as the
traditional Japanese Kampo medicine.
Case presentation: A 12-year-old girl was admitted to our hospital for intermittent upper abdominal pain.
Radiological examinations revealed a large (9.5 × 5.8 × 10.0 cm) retroperitoneal LM, which was suspected to
adhering and stretching both pancreas head and duodenum. The large retroperitoneal tumor resection might
induce involving complications because of the size and the location. Therefore, we used TJ-28 in order to
diminish the tumor size before surgery. The patient received oral doses of 7.5 g/day (2.5 g × 3 times/day) of
TJ-28. Six months after the medication, the tumor decreased markedly to 3.5 × 1.5 × 1.2 cm in size. Thereafter,
the mass was sub-totally resected (95%) via a 3 cm trans-umbilical incision without any surgical complications.
Conclusions: We reported a case of successfully treated retroperitoneal LM with the combination treatment
of TJ-28 and surgery. Based on our experience, this TJ-28 treatment option may be very useful in treating
cases of LMs having surgical difficulties because of size and/or location.
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Background
Lymphatic malformations (LMs) usually appear as soft
compressive masses at birth and are found in all age
groups and in various parts of the body. LMs develop in
various spectrums from localized masses to diffuse infil-
tration. Morphological types of LMs are categorized
according to size and location, i.e., macrocystic, microcys-
tic, mixed macrocystic and microcystic, and diffuse types
[1, 2]. Although LMs are benign malformation, some-
times, its treatment can be challenging, depending on the
tumor size and location. Current multimodal treatments
include observation, sclerotherapy, radiofrequency abla-
tion, laser therapy, and surgery [2]. Recently, oral medica-
tions such as sildenafil, propranolol, and sirolimus are
shown to be effective for treating LMs [3–6]. In addition,
in Japan, the most common treatment options include
sclerotherapy using OK-432 and/or surgical resection.
Recently, several investigators have reported on the effect-
iveness of Eppikajyutsuto (TJ-28) in treating LMs [7, 8],
which is a Japanese Kampo medicine manufactured by
Tsumura & Co. (Tokyo, Japan). We experienced a suc-
cessfully treated case of large retroperitoneal LMs with
the combination treatment of TJ-28 and surgery. There-
fore, we herein reported the clinical course of this case
and showed the effectiveness of our treatment.
Case presentation
A 12-year-old girl was admitted to our hospital for
intermittent upper abdominal pain, which continued
for 3 days. The patient had no past medical histories.
On admission, the patient had upper abdominal pain,
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nausea, and vomiting. The patient had no history associ-
ated with antecedent infections or abdominal contusions.
A physical examination revealed a smooth and elastic hard
mass measuring 10 cm in diameter at the center of her
right flank. The patient did not have fever elevation. The
patient had spontaneous pain and tenderness on and
around the mass. Except for a slight elevation of CRP
level, which was 1.22 mg/dl, her laboratory data indicated
normal and the levels of tumor makers were also within
the normal range. Ultrasound sonography (US) showed a
large mass consisting of multi-macrocystic lesions. Con-
trast CT revealed a well-circumscribed multicystic mass
measuring 9.5 × 5.8 × 10.0 cm in the retroperitoneal
region. The mass, which is filled with serous fluid without
hemorrhage or abscess, was suspected to adhering and
stretching both pancreas head and duodenum (Fig. 1a, b).
This well-circumscribed multicystic mass showed to be
hypointense on T1 images and hyperintense on T2 images
of magnetic resonance imaging (MRI) (Fig. 2a). The mass
did not contain any fat tissue. According to the radio-
logical findings, the mass was diagnosed as a large retro-
peritoneal LM. After intestinal rest therapy, her symptoms
disappeared and she was discharged on the 5th day after
admission. Tumor resection was considered necessary
because of avoiding the recurrence of acute abdomen.
However, we thought that the large retroperitoneal tumor
resection might induce involving complications because of
adhesion of the mass to both pancreas head and duo-
denum. To deal with this issue, we used a traditional
Japanese Kampo medicine, Eppikajyutsuto (TJ-28), in
order to diminish the tumor size before surgery. On
3 weeks after the symptoms onset, the patient re-
ceived oral doses of 7.5 g/day (2.5 g × 3 times/day) of
TJ-28. The patient received regular physical examin-
ation and US. On six months after the medication
began, her MRI revealed that the tumor size de-
creased markedly to 3.5 × 1.5 × 1.2 cm in size (Fig. 2b).
No side effects from TJ-28 were observed. Thereafter,
we performed surgical resection, and the mass was
sub-totally resected (95%) via a 3 cm trans-umbilical
and longitudinal incision without any surgical compli-
cations. The cystic wall was thickened and the cystic
fluid was yellowish serous with containing lympho-
cytes. The histological findings showed that the wall
of the cystic mass had hyaline degeneration and the
endothelium was not existed (Fig. 3). TJ-28 was con-
tinued for 1 month after the surgery. The patient’s
postoperative course has been uneventful, and there
have been no recurrences in over 3 years after the
surgery.
Discussion
Although the effectiveness of TJ-28 in treating LMs has
been reported [7, 8], it is unclear that TJ-28 can
completely resolve this large retroperitoneal LM. The
histological findings of our case suggested that TJ-28
might have an effect of degenerating the endothelium of
LMs. However, TJ-28 alone might be insufficient to
complete resolution of the residual thickened sorround-
ing fibrous wall. Therefore, we decided to use TJ-28
combining with surgical resection.
The Japanese Kampo medicine Eppikajyutsuto (TJ-28)
consists of six crude drug (herbs) components including
Sekko, Mao, Sojutsu, Taiso, Kanzo, and Shokyo. TJ-28
regulates and reduces redundant body fluids and also
a
b
Fig. 1 Contrast CT revealed a well-circumscribed multicystic mass
measuring 9.5 × 5.8 × 10.0 cm in the retroperitoneal region. The mass,
filled with serous fluid without hemorrhage or abscess, was suspected
to adhering and stretching the pancreas head (a, arrow: pancreas
head) by the beak sign. The tumor was suspected to adhering
the duodenum (b, arrow: duodenum)
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has anti-inflammatory effects. Therefore, TJ-28 is usually
used to treat edema, excessive sweating, thirst, and
decreases in urine volume. In addition, recently, several
investigators have reported on the effectiveness of TJ-28
in treating LMs [7, 8]. The purpose of TJ-28 usage in
LMs was to regulate and reduce cystic fluids. Ogawa-
Ochiai et al reported on successfully treating a case of
huge mediastinal LM with TJ-28 [7]. In that case, the
tumor volume was greatly reduced after TJ-28 therapy.
Hashizume et al. also reported on eight cases of LMs
that have been successfully treated with TJ-28 [8]. Based
on their experiences, they discussed on the function
of Mao (ephedra herb), which is a main component
of TJ-28. Mao (ephedra herb) is suggested to work
for the suppression of vascular endothelial growth
factor (VEGF) activity by inhibiting prostaglandin E2
synthesis and cyclooxygenase protein synthesis [9–11].
VEGF is recognized as a key regulator of lymphangio-
genesis. It has been reported that the pathogenesis of
LMs is associated with various types of gene mutation
of VEGF and high expression of VEGF in LMs [12].
Therefore, TJ-28 may suppress VEGF activity and reduce
cystic fluids, which in turn induces LM shrinkage. In
addition, this functional mechanism of TJ-28 may be con-
sidered to be similar to that of sirolimus [5, 6, 13]. Accord-
ing to the histological findings of the wall of the resected
specimen, TJ-28 can affect on lymphatic endothelium by
inducing endothelial degeneration. However, further
investigation is necessary to find the pharmacological
mechanism of TJ-28 to LMs.
Our objectives include realizing a better cosmetic out-
come as well as minimizing surgical complications.
Conclusions
We reported a case of successfully treated retroperiton-
eal LM with the combination treatment of TJ-28 and
surgery. Based on our experience, this TJ-28 treatment
option may be very useful in treating cases of LMs
having surgical difficulties because of size and/or
location.
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Fig. 2 At the first admission, magnetic resonance imaging (MRI)
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Fig. 3 The histological findings showed that the wall of the cystic
mass had hyaline degeneration and the endothelium was not existed
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